Standard BioTools Inc
NASDAQ:LAB
Standard BioTools Inc
NASDAQ:LAB
Price:
2.48 USD
-1.2%
Market Closed
Updated:
May 7, 2024
Standard BioTools Inc
Operating Income
|
Standard BioTools Inc
Operating Income Peer Comparison
Comparables:
TMO
DHR
WST
A
IQV
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Standard BioTools Inc
NASDAQ:LAB
|
Operating Income
-$63m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-14%
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Operating Income
$7.3B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
14%
|
CAGR 10-Years
15%
|
|
|
Danaher Corp
NYSE:DHR
|
Operating Income
$9.5B
|
CAGR 3-Years
20%
|
CAGR 5-Years
26%
|
CAGR 10-Years
12%
|
|
|
West Pharmaceutical Services Inc
NYSE:WST
|
Operating Income
$661.6m
|
CAGR 3-Years
9%
|
CAGR 5-Years
20%
|
CAGR 10-Years
15%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Operating Income
$1.3B
|
CAGR 3-Years
11%
|
CAGR 5-Years
6%
|
CAGR 10-Years
16%
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Operating Income
$2.1B
|
CAGR 3-Years
38%
|
CAGR 5-Years
21%
|
CAGR 10-Years
16%
|
See Also
What is Standard BioTools Inc's Operating Income?
Operating Income
-63m
USD
-63m
USD
Based on the financial report for Dec 31, 2023, Standard BioTools Inc's Operating Income amounts to -63m USD.
What is Standard BioTools Inc's Operating Income growth rate?
Operating Income CAGR 10Y
-14%
-14%
Over the last year, the Operating Income growth was 46%. The average annual Operating Income growth rates for Standard BioTools Inc have been -7% over the past three years , -6% over the past five years , and -14% over the past ten years .
You don't have any saved screeners yet
